5 Important Takeaways From Cronos Group’s (TSX:CRON) Latest Quarterly Earnings

Here’s what you need to know about Cronos Group’s (TSX:CRON)(NASDAQ:CRON) latest quarterly financial results.

| More on:
Man holding magnifying glass over a document

Image source: Getty Images.

A sequential quarterly net revenue growth of 24% and a 214% jump in quarterly net earnings to $788 million could top the highlights for Cronos Group’s (TSX:CRON)(NASDAQ:CRON) latest financial report delivered early on Tuesday, but there was a lot to chew in the company’s latest quarterly results.

Let’s just quickly get down to it.

Revenue growth was aided

Cronos reported a sequential revenue growth of 24% over the third quarter to $12.7 million, which was a 238% year-over-year increase in the top line, but this growth included newly acquired Redwood’s revenue from U.S. hemp operations.

Adjusting for this recent acquisition, cannabis gross revenues increased only by 15% sequentially, as cannabis oil sales significantly shrank in half, and there was a negative revenue recognition in international dry cannabis sales, which may need further investigation, as this charge represented about half of international dried product sales recognized during the second quarter.

The big question is, what could have driven this export revenue charge when the company is supposed to be one of the best-placed pot growers to capture a growing Germany medical marijuana market?

Shrinking gross margins

The company’s adjusted gross margins were significantly compressed to 41%, down from 53% of revenue, as realized product prizes declined and high-margin extracts sales declined.

Management mentioned that the majority of sales happened in the wholesale market, and this should explain why margins suffered. Another licensed producer, HEXO, had a nasty experience with the wholesale market recently.

A strong 98% growth in kilograms sold

The company grew its sales volumes by about 98% to 3,142 kilograms of cannabis over three months to September, as compared to the June-ended quarter. This was supposed to be an impressive achievement, but, disappointingly, the product was sold at an average price of $3.75 per gram, down 42% from $6.44 a gram in the previous quarter.

Volumes have grown, but there wasn’t a meaningful corresponding increase in booked revenue due to a severe weakness in selling prices.

Pricing pressures are indeed showing up in the nascent marijuana industry, and that’s discouraging for growth investors.

Slightly improved cash burn

The company used “only” $26.4 million in operating activities during the third quarter, down from $57.4 million during the second quarter.

A lower cash spend rate could help maintain a healthy balance sheet in the near term, even as the strategic acquisition of hemp operations from Redwood during the quarter drained $301 million from the cash book.

Company to re-purpose parts of its largest grow facility

One of the biggest surprises from Cronos management was the announcement that the company intends to re-purpose some facilities at its Peace Naturals Campus (the company’s biggest functional production facility) from cultivation activities to research and development activities and storage and warehousing functions.

This move is likely to result in a one-time charge of about $15 million to the income statement mostly for the current fourth quarter.

The company ranks very low on productive capacity in the industry with a proforma capacity of just over 115,000 kilograms per annum once the other facilities under construction are brought online. Productive capacity could therefore decline soon.

Investor takeaway

The company’s balance sheet remains intact with nearly $2 billion in cash, cash equivalents, and short-term investments on the balance sheet, but I wish there could be more revenue growth and improvements in operating earnings.

Pricing pressures may have come too early to this young industry, and the company should reduce its costs per gram further and grow extracts sales to protect threatened margins while progress is required on the export front.

Overall, this was a mixed quarter, but the stock price responded positively, as investors liked the massive bottom-line profit, which was largely a gain on derivative contracts.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »